» Articles » PMID: 27080480

Population-standardized Genetic Risk Score: the SNP-based Method of Choice for Inherited Risk Assessment of Prostate Cancer

Overview
Journal Asian J Androl
Specialty Urology
Date 2016 Apr 16
PMID 27080480
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Several different approaches are available to clinicians for determining prostate cancer (PCa) risk. The clinical validity of various PCa risk assessment methods utilizing single nucleotide polymorphisms (SNPs) has been established; however, these SNP-based methods have not been compared. The objective of this study was to compare the three most commonly used SNP-based methods for PCa risk assessment. Participants were men (n = 1654) enrolled in a prospective study of PCa development. Genotypes of 59 PCa risk-associated SNPs were available in this cohort. Three methods of calculating SNP-based genetic risk scores (GRSs) were used for the evaluation of individual disease risk such as risk allele count (GRS-RAC), weighted risk allele count (GRS-wRAC), and population-standardized genetic risk score (GRS-PS). Mean GRSs were calculated, and performances were compared using area under the receiver operating characteristic curve (AUC) and positive predictive value (PPV). All SNP-based methods were found to be independently associated with PCa (all P < 0.05; hence their clinical validity). The mean GRSs in men with or without PCa using GRS-RAC were 55.15 and 53.46, respectively, using GRS-wRAC were 7.42 and 6.97, respectively, and using GRS-PS were 1.12 and 0.84, respectively (all P < 0.05 for differences between patients with or without PCa). All three SNP-based methods performed similarly in discriminating PCa from non-PCa based on AUC and in predicting PCa risk based on PPV (all P > 0.05 for comparisons between the three methods), and all three SNP-based methods had a significantly higher AUC than family history (all P < 0.05). Results from this study suggest that while the three most commonly used SNP-based methods performed similarly in discriminating PCa from non-PCa at the population level, GRS-PS is the method of choice for risk assessment at the individual level because its value (where 1.0 represents average population risk) can be easily interpreted regardless of the number of risk-associated SNPs used in the calculation.

Citing Articles

Predicting 10-Year Risk of Pancreatic Cancer Using a Combined Genetic and Clinical Model.

Dite G, Spaeth E, Wong C, Murphy N, Allman R Gastro Hep Adv. 2024; 2(7):979-989.

PMID: 39130772 PMC: 11308393. DOI: 10.1016/j.gastha.2023.05.008.


Comparative analysis of genetic risk scores for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy.

Hsieh A, Luo Y, Bao B, Chou T BMC Urol. 2024; 24(1):136.

PMID: 38956663 PMC: 11218119. DOI: 10.1186/s12894-024-01524-6.


Utility of polygenic scores across diverse diseases in a hospital cohort for predictive modeling.

Sun T, Wang C, Liu T, Lo S, Huang Y, Chien S Nat Commun. 2024; 15(1):3168.

PMID: 38609356 PMC: 11014845. DOI: 10.1038/s41467-024-47472-5.


Antioxidant enzyme and DNA base repair genetic risk scores' associations with systemic oxidative stress biomarker in pooled cross-sectional studies.

Mao Z, Gray A, Thyagarajan B, Bostick R Front Aging. 2023; 4:1000166.

PMID: 37152862 PMC: 10161255. DOI: 10.3389/fragi.2023.1000166.


Determining the role of genetic risk scores in symptomatic cancer detection.

Bailey S, Butler C, Katsampouris E, Kessler L, Quaife S, Saya S Br J Gen Pract. 2023; 73(728):106-107.

PMID: 36823064 PMC: 9976822. DOI: 10.3399/bjgp23X732069.


References
1.
Hoffmann T, Van Den Eeden S, Sakoda L, Jorgenson E, Habel L, Graff R . A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. Cancer Discov. 2015; 5(8):878-91. PMC: 4527942. DOI: 10.1158/2159-8290.CD-15-0315. View

2.
Pashayan N, Duffy S, Neal D, Hamdy F, Donovan J, Martin R . Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Med. 2015; 17(10):789-95. PMC: 4430305. DOI: 10.1038/gim.2014.192. View

3.
Nordstrom T, Aly M, Eklund M, Egevad L, Gronberg H . A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml. Eur Urol. 2013; 65(6):1184-90. DOI: 10.1016/j.eururo.2013.07.005. View

4.
Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-90. PMC: 6027585. DOI: 10.1056/NEJMoa1113135. View

5.
Yamada H, Penney K, Takahashi H, Katoh T, Yamano Y, Yamakado M . Replication of prostate cancer risk loci in a Japanese case-control association study. J Natl Cancer Inst. 2009; 101(19):1330-6. DOI: 10.1093/jnci/djp287. View